ArticleMolecular neurobiology2019
Biased G Protein-Independent Signaling of Dopamine D
Open access · greenAbstract read
In one paragraph
Article in Molecular neurobiology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.
0numbers the graph read from it
0cells of the map it votes in
27citing papers in PubMed
2.6field-weighted citation impact, top 10% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 38 citations in OpenAlex.
- Mechanistic and therapeutic insights into class A GPCR dimers in neuropsychiatric disorders.npj drug discovery · 2026Review
- Review
- GPCR Heterodimers: Implications for Biased Signaling.Handbook of experimental pharmacology · 2026Review
- Activation of dimerized BRS3-EP3 suppresses melanoma cell migration through coupling GαFundamental research · 2025Article
- Distinctive biochemical properties of the μ-opioid receptor-corticotropin- releasing factor CRFPharmacological research · 2025Article
- Locomotor activity depends on β-arrestin recruitment by the dopamine DPharmacological research · 2025Article
- Unveiling the Differences in Signaling and Regulatory Mechanisms between Dopamine DInternational journal of molecular sciences · 2023Review
- G Protein-Dependent Activation of the PKA-Erk1/2 Pathway by the Striatal Dopamine D1/D3 Receptor Heteromer Involves Beta-Arrestin and the Tyrosine Phosphatase Shp-2.Biomolecules · 2023Article
- The World of GPCR dimers - Mapping dopamine receptor DComputational and structural biotechnology journal · 2023Article
- Pharmacological targeting of G protein-coupled receptor heteromers.Pharmacological research · 2022Article
- G protein-coupled receptor-effector macromolecular membrane assemblies (GEMMAs).Pharmacology & therapeutics · 2022Review
- Neurobiological and Pharmacological Perspectives of D3 Receptors in Parkinson's Disease.Biomolecules · 2022Review
- Class A and C GPCR Dimers in Neurodegenerative Diseases.Current neuropharmacology · 2022Review
- Involvement of Basolateral Amygdala Dopamine D1 Receptors in the Acquisition and Expression of Morphine-Induced Place Preference in Rats.Advanced biomedical research · 2022Article
- Heteromerization between αPharmacological research · 2021Article
- Dopamine D3 Receptor Plasticity in Parkinson's Disease and L-DOPA-Induced Dyskinesia.Biomedicines · 2021Review
- Neuronal Dopamine D3 Receptors: Translational Implications for Preclinical Research and CNS Disorders.Biomolecules · 2021Review
- Cell-Type-Specific Adaptions in Striatal Medium-Sized Spiny Neurons and Their Roles in Behavioral Responses to Drugs of Abuse.Frontiers in synaptic neuroscience · 2021Review
- Immunomodulatory Effects of Dopamine in Inflammatory Diseases.Frontiers in immunology · 2021Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 4 institutions in 2 countries.
Xavier GuitartIntegrative Neurobiology Section, National Institute on Drug Abuse, Intramural Research Program, National Institutes of Health, Baltimore, MD, 21224, USA.
Estefanía MorenoDepartment of Biochemistry and Molecular Biomedicine of the Faculty of Biology and Institute of Biomedicine of the University of Barcelona and Center for Biomedical Research in Neurodegenerative Diseases Network, 08028, Barcelona, Spain.
William ReaIntegrative Neurobiology Section, National Institute on Drug Abuse, Intramural Research Program, National Institutes of Health, Baltimore, MD, 21224, USA.
Marta Sánchez-SotoIntegrative Neurobiology Section, National Institute on Drug Abuse, Intramural Research Program, National Institutes of Health, Baltimore, MD, 21224, USA.
Ning-Sheng CaiIntegrative Neurobiology Section, National Institute on Drug Abuse, Intramural Research Program, National Institutes of Health, Baltimore, MD, 21224, USA.
César QuirozIntegrative Neurobiology Section, National Institute on Drug Abuse, Intramural Research Program, National Institutes of Health, Baltimore, MD, 21224, USA.
Vivek KumarMedicinal Chemistry Section, National Institute on Drug Abuse, Intramural Research Program, National Institutes of Health, Baltimore, MD, 21224, USA.
Liam BourqueIntegrative Neurobiology Section, National Institute on Drug Abuse, Intramural Research Program, National Institutes of Health, Baltimore, MD, 21224, USA.
Antoni CortésDepartment of Biochemistry and Molecular Biomedicine of the Faculty of Biology and Institute of Biomedicine of the University of Barcelona and Center for Biomedical Research in Neurodegenerative Diseases Network, 08028, Barcelona, Spain.
Enric I CanelaDepartment of Biochemistry and Molecular Biomedicine of the Faculty of Biology and Institute of Biomedicine of the University of Barcelona and Center for Biomedical Research in Neurodegenerative Diseases Network, 08028, Barcelona, Spain.
Christopher BishopBehavioral Neuroscience Program, Department of Psychology, Binghamton University, Binghamton, NY, 13902, USA.
Amy H NewmanMedicinal Chemistry Section, National Institute on Drug Abuse, Intramural Research Program, National Institutes of Health, Baltimore, MD, 21224, USA.
Vicent CasadóDepartment of Biochemistry and Molecular Biomedicine of the Faculty of Biology and Institute of Biomedicine of the University of Barcelona and Center for Biomedical Research in Neurodegenerative Diseases Network, 08028, Barcelona, Spain. vcasado@ub.edu.
Sergi FerréIntegrative Neurobiology Section, National Institute on Drug Abuse, Intramural Research Program, National Institutes of Health, Baltimore, MD, 21224, USA. sferre@intra.nida.nih.gov.ORCID http://orcid.org/0000-0002-1747-1779
National Institutes of Health · USInstitut de Biomedicina de la Universitat de BarcelonaBinghamton University · USInstitute for Research in Biomedicine · ES
Funding
Neurotransmitter Receptor Heteromers in the Striatal Spine ModuleZIADA000493 · NIDA · NATIONAL INSTITUTE ON DRUG ABUSE · PI FERRE, SERGI · 2009 to 2025
$35.6MNovel Dopamine D3 Receptor Ligands ZIADA000424 · NIDA · NATIONAL INSTITUTE ON DRUG ABUSE · PI NEWMAN, AMY HAUCK · 2009 to 2025
$25.9MNeurotransmitter Receptor Heteromers in the Striatal Spine ModuleZ01DA000493 · NIDA · NATIONAL INSTITUTE ON DRUG ABUSE · PI GOLDBERG, STEVEN R · 2006 to 2008
$691kDepartament de Salut, Generalitat de Catalunya 2017-SGR-1497Fundació la Marató de TV3 20140610Intramural NIH HHS Z01 DA000493Ministerio de Economía, Industria y Competitividad, Gobierno de España SAF2014-54840-R and SAF2017-87629-RNIDA NIH HHS Intramural Funds
Abstract
Several studies found in vitro evidence for heteromerization of dopamine D
Indexed as
Signal TransductionAnimalsCHO CellsCricetinaeCricetulusDrug SynergismGTP-Binding ProteinsHEK293 CellsHumansIsoquinolinesMaleMiceMitogen-Activated Protein KinasesModels, BiologicalMotor ActivityNucleus AccumbenseticloprideGTP-Binding ProteinsIsoquinolinesMitogen-Activated Protein KinasesN-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamidePeptidesProto-Oncogene Proteins c-aktReceptors, Dopamine D1Receptors, Dopamine D3SalicylamidesSulfonamidesDopamine D1 receptorDopamine D3 receptorFunctional selectivityGPCR heteromersReserpine
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.